CliffBio
small molecule

ENOXAPARIN SODIUM

ENOXAPARIN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyAmphastar Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameENOXAPARIN SODIUM
Active ingredientENOXAPARIN SODIUM
Strength300MG/3ML (100MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

More from Amphastar Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ENOXAPARIN SODIUM patent cliff — loss of exclusivity — | CliffBio